



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/509,078 | 09/27/2004 | Mahood Ahmend | P33024 | 1354 |

20462

7590

02/19/2008

SMITHKLINE BEECHAM CORPORATION
CORPORATE INTELLECTUAL PROPERTY-US, UW2220
P. O. BOX 1539
KING OF PRUSSIA, PA 19406-0939

EXAMINER

BERNHARDT, EMILY B

ART UNIT

PAPER NUMBER

1624

NOTIFICATION DATE

DELIVERY MODE

02/19/2008

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

US_cipkop@gsk.com

Interview Summary

Application No.

10/509,078

Applicant(s)

AHMEND ET AL.

Examiner

Emily Bernhardt

Art Unit

1624

All participants (applicant, applicant's representative, PTO personnel):

(1) Emily Bernhardt.

(3) _____.

(2) Ms. Sieburth.

(4) _____.

Date of Interview: 12 February 2008.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal (copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.
If Yes, brief description: _____.

Claim(s) discussed: Method claims.

Identification of prior art discussed: _____.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☒ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: In response to the Final Rejection, Ms. Sieburth proposed to present a claim to treating Alzheimer's Disease. The examiner advised that references be submitted including any evidence that 5-HT6 antagonists are undergoing clinical trials for said disease. The examiner will consider such but if not found persuasive, the AF amendment may be denied entry as a brand new rejection would otherwise need to be made.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

/Emily Bernhardt/
Primary Examiner, Art Unit 1624
Examiner's signature, if required

Examiner Note: You must sign this form unless it is an
Attachment to a signed Office action.